Lehman Constance D, Blume Jeffrey D, Weatherall Paul, Thickman David, Hylton Nola, Warner Ellen, Pisano Etta, Schnitt Stuart J, Gatsonis Constantine, Schnall Mitchell, DeAngelis Gia A, Stomper Paul, Rosen Eric L, O'Loughlin Michael, Harms Steven, Bluemke David A
Department of Radiology, University of Washington, Seattle Cancer Care Alliance, Seattle, Washington 98109-1023, USA.
Cancer. 2005 May 1;103(9):1898-905. doi: 10.1002/cncr.20971.
The authors compared the performance of screening mammography versus magnetic resonance imaging (MRI) in women at genetically high risk for breast cancer.
The authors conducted an international prospective study of screening mammography and MRI in asymptomatic, genetically high-risk women age >/= 25 years. Women with a history of breast cancer were eligible for a contralateral screening if they had been diagnosed within 5 years or a bilateral screening if they had been diagnosed > 5 years previously. All examinations (MRI, mammography, and clinical breast examination [CBE]) were performed within 90 days of each other.
In total, 390 eligible women were enrolled by 13 sites, and 367 women completed all study examinations. Imaging evaluations recommended 38 biopsies, and 27 biopsies were performed, resulting in 4 cancers diagnosed for an overall 1.1% cancer yield (95% confidence interval [95%CI], 0.3-2.8%). MRI detected all four cancers, whereas mammography detected one cancer. The diagnostic yield of mammography was 0.3% (95%CI, 0.01-1.5%). The yield of cancer by MRI alone was 0.8% (95%CI, - 0.3-2.0%). The biopsy recommendation rates for MRI and mammography were 8.5% (95%CI, 5.8-11.8%) and 2.2% (95%CI, 0.1-4.3%).
Screening MRI in high-risk women was capable of detecting mammographically and clinically occult breast cancer. Screening MRI resulted in 22 of 367 of women (6%) who had negative mammogram and negative CBE examinations undergoing biopsy, resulting in 3 additional cancers detected. MRI also resulted in 19 (5%) false-positive outcomes, which resulted in benign biopsies.
作者比较了乳腺钼靶筛查与磁共振成像(MRI)在乳腺癌遗传高危女性中的表现。
作者对年龄≥25岁、无症状的乳腺癌遗传高危女性进行了一项乳腺钼靶筛查和MRI的国际前瞻性研究。有乳腺癌病史的女性,如果在5年内确诊,符合对侧乳房筛查条件;如果在5年以前确诊,则符合双侧乳房筛查条件。所有检查(MRI、乳腺钼靶和临床乳腺检查[CBE])均在彼此90天内完成。
共有13个研究点招募了390名符合条件的女性,367名女性完成了所有研究检查。影像评估建议进行38次活检,实际进行了27次活检,确诊4例癌症,总体癌症检出率为1.1%(95%置信区间[95%CI],0.3 - 2.8%)。MRI检测出全部4例癌症,而乳腺钼靶仅检测出1例癌症。乳腺钼靶的诊断检出率为0.3%(95%CI,0.01 - 1.5%)。仅MRI的癌症检出率为0.8%(95%CI, - 0.3 - 2.0%)。MRI和乳腺钼靶的活检建议率分别为8.5%(95%CI,5.8 - 11.8%)和2.2%(95%CI,0.1 - 4.3%)。
对高危女性进行MRI筛查能够检测出乳腺钼靶和临床隐匿性乳腺癌。在367名乳腺钼靶检查和CBE检查均为阴性的女性中,MRI筛查导致22名女性(6%)接受活检,额外检测出3例癌症。MRI还导致19例(5%)假阳性结果,活检结果为良性。